SCHEMBL4494716

SCHEMBL4494716

Cc1cc2nc(-c3ccccc3-c3nc4cc(C)c(C)cc4[nH]3)[nH]c2cc1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.68
RAB9A P51151 3/20 0.68
ATM Q13315 1/20 0.68
ERAP1 Q9NZ08 1/20 0.68
METAP1 P53582 2/20 0.64
METAP2 P50579 1/20 0.64
CBFB Q13951 1/20 0.64
AMY1A P0DUB6 7/20 0.62
ADORA3 P0DMS8 1/20 0.60
ALDH1A1 P00352 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
GUSB P08236 3/20 0.54
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
PDGFRB P09619 1/20 0.52
FGFR1 P11362 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946648 0.93 NPC1 (0.70) NPC1RAB9AATMERAP1METAP1
SCHEMBL3341622 0.89 GUSB (0.65) NPC1RAB9AATMERAP1METAP1
SCHEMBL12145570 0.89 AMY1A (0.59) NPC1RAB9AATMERAP1METAP1
SCHEMBL7398247 0.89 AMY1A (0.71) NPC1RAB9AATMERAP1METAP1
SCHEMBL12072142 0.89 NPC1 (0.71) NPC1RAB9AATMERAP1METAP1
SCHEMBL13203529 0.87 NPC1 (0.61) NPC1RAB9AATMERAP1METAP1
SCHEMBL1170803 0.84 FABP6 (0.63) NPC1RAB9AATMERAP1METAP1
SCHEMBL30038044 0.84 FABP6 (0.63) NPC1RAB9AATMERAP1METAP1
SCHEMBL3337332 0.84 METAP2 (0.62) NPC1RAB9AMETAP1METAP2CBFB
SCHEMBL21111643 0.83 RAB9A (0.68) NPC1RAB9AATMERAP1METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 US disclosed
US-7132439-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2006-11-07 US disclosed
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 NPC1 1216/4885RAB9A 3054/4885ATM 4022/4885
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 NPC1 1216/4885RAB9A 3054/4885ATM 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.